CClinicalTrials.gg
CompletedNCT03269123Updated Aug 31, 2017

A Mechanical Device for Blepharospasm

An interventional study of Pressop 1 in Blepharospasm, sponsored by Oxford University Hospitals NHS Trust. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-31.

Sponsored by Oxford University Hospitals NHS Trust · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Idiopathic blepharospasm (IB) is a rare but well characterised adult onset focal dystonia that may cause severe visual disability. The most effective treatment is with periodic injections of botulinum toxin into the pre-tarsal and / or pre-septal orbicularis oculi muscles bilaterally. However, even with treatment, practical visual function often remains compromised.

A subset of IB sufferers find that eye opening improves with focal unilateral digital pressure usually on a specific point on the temple. The Investigators have developed a spectacle mounted spring-loaded prosthesis (the "Pressop" device) to apply continuous individually localised focal pressure on the temple to mimic the effect of finger pressure.

The Investigators recommended a trial of this simple safe device in those IB patients who report improvement in eye opening with focal digital temple pressure.

Read the detailed description

Idiopathic blepharospasm is a rare chronic neuro-ophthalmic disorder that causes substantial visual handicap \& compromises quality of life. It affects adults, women more than men, usually beginning in the 5th or 6th decade and consists of repeated forceful bilateral spasms of eye closure with photophobia and ocular surface discomfort. In up to a third of cases there are synchronous mid and / or lower facial spasms and the spectrum of disorder extends to cranial dystonia involving jaw \& neck muscle spasms (e.g. antecollis or retrocollis). Practical visual function is variably affected but most patients will have to stop driving, many cannot work, manage the house or even leave the house unaccompanied. Leisure activities such as reading \& watching television are compromised or impossible, and secondary mood dysphoria and depression are common.

In some cases, patients have discovered that applying focal finger pressure, usually to the temple, relieves or even abolishes the spasms for the duration of the application. It is, however, difficult for the patient to sustain the finger pressure and impossible to apply it during activities when eyesight is important e.g. driving, typing or other bimanual tasks. The phenomenon can be regarded as the equivalent of the sensory trick (ST or geste antagonistique) seen in some cases of spasmodic torticollis whereby finger tip pressure on the chin prevents or reduces the muscle spasms in the neck and allows the head to be held straight.

In this study, the Investigators explored the hypothesis that the benefit of the finger-tip pressure sensory trick could be replicated by a spring-loaded, spectacle mounted device applying focal pressure to the temple. Following preliminary design trials, the investigators commissioned a manufacturer to develop a light easily handled pressure device that could be fixed to the frame of most spectacles. The "Pressop" device fulfils these criteria and was adopted for the trial.

02

Conditions studied

  • Blepharospasm

Browse trials for

Keywords

  • Sensory trick
  • Geste Antagoniste
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Any adult patient with Blepharospasm of sufficient severity to necessitate repeated Botulinum injections can be included in the study.
  • It is not essential for participants to be spectacle wearers (having a refractive error) as prescription free (zero power) spectacles can be provided for the purposes of being able to trial the device .
  • The participants may or may not be currently having Botulinum Toxin injections. Some of these patients will be known to use the "Geste Antagoniste" phenomenon. Patients who may not know of this potential therapeutic effect will also be invited to trial the device.

Exclusion criteria

Exclusion Criteria:

  • Inability to wear spectacles due to any reason (as the device has to be mounted on the spectacle frame).
  • Patients who have spasms and twitches of the eyes caused by a different pathology e.g. Hemi facial Spasm, Parkinson's disease will also be excluded from this trial.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Other
    A device to relieve Blepharospasm

    The pressure device known as Pressop1 is the intervention which is attached to the spectacles and worn for 2 weeks prior to retreatment with Botulinum Toxin injections to assess its effectiveness in controlling eyelid spasms.

    Device: Pressop 1

Interventions

  • DevicePressop 1

    A pressure device attached to the spectacles which mimics a sensory trick (geste Antagoniste)

05

What researchers measure

Primary outcomes

  1. The study's objective and subjective responses for the use of the device is measured with the CDQ-24 questionnaire and a questionnaire specific to the the device

    Outcome measures will be taken from the CDQ-24 assessment carried out before and after using the pressure device demonstrating improved quality of life.The questionnaire specific to the device addresses issues like wearing time, discomfort, suggestions and feedback .

    Time frame: 2-3 week trial period

Secondary outcomes

  1. The proportion of patients demonstrating the "Geste Antagoniste" phenomenon.

    This proportion will be presented, along with its 95% confidence interval

    Time frame: 2-3 week trial period

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No — The study findings will be published in the appropriate medical journal

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03269123
Lead sponsor
Oxford University Hospitals NHS Trust
Collaborators
The Dystonia Society of the United Kingdom, Globsource UK, Statsconsultancy Ltd, Amersham, Buckinghamshire,UK
Responsible party
Alexina Fantato (Principal Investigator, Oxford University Hospitals NHS Trust) — Principal investigator
First posted
Aug 31, 2017
Start date
Mar 2, 2010
Primary completion
Aug 8, 2011
Completion
Aug 8, 2011
Last update
Aug 31, 2017

Study contacts

John S Elston, MD FRCS OPTH
study director · Oxford University Hospitals NHS Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion